Sangamo Therapeutics has initiated a critical regulatory process for its investigational gene therapy targeting Fabry disease. The biotechnology firm has commenced a rolling submission of a Biologics ...

The investment case for Palantir Technologies continues to be defined by its central role in the artificial intelligence revolution. While operational performance hits new records, the stock's premium ...